25/02/2026
๐ฅ๐ฒ๐ฑ๐ฒ๐ณ๐ถ๐ป๐ถ๐ป๐ด ๐ฃ๐ฟ๐ผ๐๐๐ฎ๐๐ฒ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐๐ฎ๐ฟ๐ฒ ๐ถ๐ป ๐๐๐ป๐ด๐ฎ๐ฟ๐ ๐
A new chapter in minimally invasive prostate cancer treatment has begun in Hungary. The ๐ณ๐ถ๐ฟ๐๐-๐ฒ๐๐ฒ๐ฟ Focal One ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐๐ were successfully performed at ๐ฆ๐. ๐ ๐ฎ๐ด๐ฑ๐ผ๐น๐ป๐ฎ ๐๐ผ๐๐ฝ๐ถ๐๐ฎ๐น ๐ถ๐ป ๐๐๐ฑ๐ฎ๐ฝ๐ฒ๐๐, ๐๐๐ป๐ด๐ฎ๐ฟ๐ marking an important step forward in expanding access to advanced, organ-preserving therapies.
This achievement reflects what is possible when expertise, technology, and collaboration align seamlessly. The procedures were carried out by ๐๐ฟ. ๐๐๐๐ถ๐น๐ฎ ๐ ๐ฒ๐๐๐ฒ๐-๐งรณ๐๐ต ๐ ๐ and ๐๐ฟ. ๐ญ๐๐ผ๐น๐ ๐รก๐๐ถ ๐ ๐, with proctoring support from ๐ฃ๐ฟ๐ผ๐ณ. ๐๐ถ๐ผ๐๐ฎ๐ป๐ป๐ถ ๐๐๐ด๐ต๐ฒ๐๐๐ฎ๐ป๐ถ, ensuring clinical excellence at every stage.
Focal therapy represents a meaningful ๐ฒ๐๐ผ๐น๐๐๐ถ๐ผ๐ป ๐ถ๐ป ๐ฝ๐ฟ๐ผ๐๐๐ฎ๐๐ฒ ๐ฐ๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ฐ๐ฎ๐ฟ๐ฒ. By targeting only the cancerous portion of the prostate while ๐ฝ๐ฟ๐ฒ๐๐ฒ๐ฟ๐๐ถ๐ป๐ด surrounding ๐ต๐ฒ๐ฎ๐น๐๐ต๐ ๐๐ถ๐๐๐๐ฒ, it offers patients an effective alternative to radical surgery, reducing side effects, supporting faster recovery, and maintaining future treatment options.
For us, milestones like this reaffirm our ๐ฐ๐ผ๐บ๐บ๐ถ๐๐บ๐ฒ๐ป๐ ๐๐ผ ๐ฒ๐
๐ฝ๐ฎ๐ป๐ฑ๐ถ๐ป๐ด ๐ฎ๐ฐ๐ฐ๐ฒ๐๐ ๐๐ผ ๐น๐ถ๐ณ๐ฒ-๐๐ฎ๐๐ถ๐ป๐ด ๐ถ๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป and supporting healthcare professionals with technologies that improve patient outcomes. Because progress in medicine happens when people, purpose, and precision come together.
๐๐ฒ๐ฎ๐ฟ๐ป ๐บ๐ผ๐ฟ๐ฒ ๐ฎ๐ฏ๐ผ๐๐ Focal One and how it is redefining prostate cancer treatment: sofmedica.com/products/focal-one